Legacy Medical Device Cybersecurity: Finding the Right Balance Between Risk, Resources, and Reality
The challenge: long product lives, changing threats
A medical device can remain clinically useful long after its underlying technology has aged. Across a legacy portfolio, manufacturers may face unsupported operating systems, third-party components with limited update paths, incomplete software inventories, and security documentation that predates current expectations. Some products are connected to hospital networks; others have limited interfaces. Their exposure, potential impact, and available remediation options differ substantially.
That variation makes a single checklist an imperfect strategy. Manufacturers must balance patient safety, operational continuity, installed-base obligations, regulatory considerations, and the engineering effort required to maintain older designs. The most consequential question is often simple: what cybersecurity support is necessary and feasible for each product, and how can the organization demonstrate the reasoning behind that decision?
What does a defensible legacy security strategy look like?
There is no universal control set that makes every legacy device secure. A credible baseline is a set of documented decisions and repeatable activities, scaled to the device’s risk and supportability. At a minimum, manufacturers should be able to:
Identify the products and versions still in use, their lifecycle status, installed base, and relevant connectivity or exposure.
Collect available architecture, software-component, security-control, vulnerability, and maintenance documentation, while recording gaps.
Assess plausible cybersecurity threats and vulnerabilities in the context of clinical use, exploitability, potential patient harm, and business or operational consequences.
Establish a process to monitor relevant vulnerabilities, receive reports, evaluate impact, communicate with customers, and coordinate response.
Determine feasible mitigations, including patches where supportable and compensating measures where they are not; assign ownership and priorities.
Document product-specific support commitments, limitations, escalation criteria, and a roadmap for remediation, continued support, or retirement.
These activities provide a starting framework, not a claim of automatic regulatory compliance. Actual obligations and appropriate measures depend on the device, market, risk profile, and applicable requirements.
MedSec’s Strategy: triage first, assess deeply where warranted
The most efficient approach begins at the portfolio level. A manufacturer with dozens of legacy product families should not need to perform the same exhaustive technical assessment on every device before knowing which ones deserve attention first.
Phase 0: Portfolio triage and baseline. MedSec reviews product inventory, lifecycle and market presence, installed base, available documentation, and known support constraints. The team identifies documentation gaps, assesses readiness and supportability, and considers technical, business, and regulatory factors. The result is an assessment summary, prioritization matrix, documentation gap analysis, and recommendations for which products should advance to detailed review.
Phase 1: Product-specific security assessment and support planning. For prioritized products, MedSec examines architecture, existing security controls, software components, vulnerability exposure, and the potential impact of identified weaknesses. Findings inform realistic remediation options and the cybersecurity support requirements for that product. Deliverables include a security assessment, vulnerability findings, support matrix, and implementation roadmap.
Phase 2: Implementation and Ongoing Cybersecurity Support. A cybersecurity strategy is only as effective as its execution. Once priorities are established and product-specific support plans are developed, MedSec helps manufacturers put those plans into action. Recognizing that every manufacturer has different internal capabilities, resources, and product complexities, MedSec offers flexible engagement models ranging from high-touch, hands-on implementation support to targeted advisory assistance. Depending on the manufacturer's needs, this may include vulnerability management, remediation planning and execution, evaluation of compensating controls, cybersecurity documentation, and ongoing risk monitoring. MedSec can work alongside internal engineering, quality, regulatory, and product security teams to address complex technical challenges, provide specialized expertise where gaps exist, or serve as a trusted advisor as the manufacturer executes its own plan. This flexible approach allows manufacturers to right-size their cybersecurity investment while maintaining a structured, risk-based strategy for managing legacy devices throughout their remaining product lifecycle.
Consider two products in the same portfolio: a widely deployed, network-connected system running unsupported software, and a low-connectivity device approaching retirement. Their support decisions may look very different. A risk-based process makes those differences explicit and defensible rather than allowing product age alone to dictate priorities.
The outcome: a support strategy manufacturers can execute
A useful legacy cybersecurity program produces more than a list of vulnerabilities. It establishes which products warrant investment first, what actions are technically possible, what residual risks require management, and what customers can reasonably expect from ongoing support. It also gives engineering, quality, regulatory, product management, and leadership a common basis for decisions.
MedSec’s approach connects portfolio-level triage to device-specific technical analysis, actionable support planning, and strategy execution. This helps manufacturers avoid spending deeply on every product before understanding their relative exposure, while still providing a path to more rigorous assessment where the risk warrants it. The intended result is clearer cybersecurity risk visibility, prioritized remediation, documented support requirements, and a practical roadmap for post-market action.
Legacy devices will not all be brought to the security posture of a newly designed product. But manufacturers can establish a thoughtful, evidence-based plan for the devices that remain in service. The first step is knowing what is in the portfolio, where the risks lie, and what support each product needs.
MedSec helps medical device manufacturers turn those questions into a structured assessment and an executable cybersecurity support strategy.
To discuss a legacy portfolio assessment, connect with MedSec.
Comments